Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 2
1961 1
1993 1
1995 1
1996 1
1997 1
1998 1
2000 2
2001 1
2006 1
2007 1
2009 1
2011 2
2013 3
2015 2
2016 6
2017 4
2018 3
2019 7
2020 6
2021 10
2022 9
2023 6

Text availability

Article attribute

Article type

Publication date

Search Results

64 results

Results by year

Filters applied: . Clear all
Page 1
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D; STEP 4 Investigators. Rubino D, et al. JAMA. 2021 Apr 13;325(14):1414-1425. doi: 10.1001/jama.2021.3224. JAMA. 2021. PMID: 33755728 Free PMC article. Clinical Trial.
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O'Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT; STEP 3 Investigators. Wadden TA, et al. Among authors: rubino dm. JAMA. 2021 Apr 13;325(14):1403-1413. doi: 10.1001/jama.2021.1831. JAMA. 2021. PMID: 33625476 Free PMC article. Clinical Trial.
Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5.
Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B, Lingvay I, Thomsen M, Wadden TA, Wharton S, Wilding JPH, Rubino D. Kushner RF, et al. Among authors: rubino d. Obesity (Silver Spring). 2020 Jun;28(6):1050-1061. doi: 10.1002/oby.22794. Obesity (Silver Spring). 2020. PMID: 32441473 Free PMC article. Clinical Trial.
A Systematic Review of Dietary Supplements and Alternative Therapies for Weight Loss.
Batsis JA, Apolzan JW, Bagley PJ, Blunt HB, Divan V, Gill S, Golden A, Gundumraj S, Heymsfield SB, Kahan S, Kopatsis K, Port A, Parks EP, Reilly CA, Rubino D, Saunders KH, Shean R, Tabaza L, Stanley A, Tchang BG, Gundumraj S, Kidambi S. Batsis JA, et al. Among authors: rubino d. Obesity (Silver Spring). 2021 Jul;29(7):1102-1113. doi: 10.1002/oby.23110. Obesity (Silver Spring). 2021. PMID: 34159755 Free PMC article. Review.
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D, Batterham RL. Lau DCW, et al. Among authors: rubino d. Lancet. 2021 Dec 11;398(10317):2160-2172. doi: 10.1016/S0140-6736(21)01751-7. Epub 2021 Nov 16. Lancet. 2021. PMID: 34798060 Clinical Trial.
Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss.
Wharton S, Calanna S, Davies M, Dicker D, Goldman B, Lingvay I, Mosenzon O, Rubino DM, Thomsen M, Wadden TA, Pedersen SD. Wharton S, et al. Among authors: rubino dm. Diabetes Obes Metab. 2022 Jan;24(1):94-105. doi: 10.1111/dom.14551. Epub 2021 Oct 4. Diabetes Obes Metab. 2022. PMID: 34514682 Free PMC article. Clinical Trial.
Management of malignant cutaneous wounds in oncologic patients.
Starace M, Carpanese MA, Pampaloni F, Dika E, Pileri A, Rubino D, Alessandrini A, Zamagni C, Baraldi C, Misciali C, Patrizi A, Bianchi T, Apalla Z, Piraccini BM. Starace M, et al. Among authors: rubino d. Support Care Cancer. 2022 Sep;30(9):7615-7623. doi: 10.1007/s00520-022-07194-0. Epub 2022 Jun 8. Support Care Cancer. 2022. PMID: 35672478 Free PMC article.
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, Lau DCW. Enebo LB, et al. Among authors: rubino dm. Lancet. 2021 May 8;397(10286):1736-1748. doi: 10.1016/S0140-6736(21)00845-X. Epub 2021 Apr 22. Lancet. 2021. PMID: 33894838 Clinical Trial.
64 results